- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07810205
Prospective Longitudinal Cohort Study of Implant Age, Pocket Plane, Incision, Surface Texture, and Volume as Predictors of Breast Implant Rupture
September 2, 2026 updated by: Research Inc
This prospective dynamic cohort will follow women with intact aesthetic silicone breast implants to evaluate predictors of rupture.
Implant age, pocket plane, incision route, surface texture, and volume will be recorded, and participants will undergo annual clinical and imaging surveillance for up to five years.
Confirmed rupture will require MRI or operative evidence.
Delayed-entry survival models will estimate the independent association of implant and surgical characteristics with rupture risk.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Women with new or existing aesthetic silicone breast implants will enter the cohort only after baseline assessment confirms that the analyzed implant is intact.
Implant and operative characteristics will be verified from device cards and operative records whenever possible.
Annual high-resolution ultrasound will screen for integrity loss, with MRI or surgery used for confirmation under a standardized algorithm.
Implant age will serve as the survival time scale, and prevalent implants will enter at their age on enrollment.
The study will estimate rupture-free survival, symptomatic and silent rupture rates, adjusted predictor effects, and management after detection.
Study Type
Observational
Enrollment (Estimated)
3000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Juan Velez, MD, Plastic surgeon
- Phone Number: +57 3054511588
- Email: info@velezlara.com
Study Locations
-
-
-
Medellín, Colombia
- Recruiting
- IQ interquirofanos
-
Contact:
- juan Velez, MD, Plastic surgeon
- Phone Number: +57 3054511588
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Adult women with aesthetic silicone breast implants documented as intact at cohort entry, including new implant recipients and prevalent implant carriers.
Description
Inclusion Criteria:
- Female sex and age 18 years or older.
- Aesthetic breast augmentation with permanent silicone implants.
- Known implantation date or sufficiently precise implantation year, pocket plane, incision route, surface texture, and implant volume.
- Both implants or the analyzed implant documented as intact at baseline by the study imaging algorithm.
- Ability to complete annual surveillance for up to five years.
- Written informed consent.
Exclusion Criteria:
- Reconstructive implantation after mastectomy, congenital deformity, or major trauma.
- Tissue expander or nonpermanent device.
- Confirmed rupture at cohort entry for the implant under analysis.
- PIP implant or another recalled device if the final protocol elects to exclude it from etiologic modeling.
- Missing core implant characteristics or implantation date.
- Planned immediate explantation or exchange at enrollment for a reason unrelated to surveillance.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Aesthetic Breast Implant Surveillance Cohort
Women with intact silicone implants at enrollment are followed prospectively.
Pocket plane, incision, texture, volume, and implant age are modeled as exposures rather than recruitment groups.
|
Implant-level exposure data include implantation date, laterality, pocket plane, incision route, surface texture, shape, volume, manufacturer/lot when available, primary versus revision placement, and concomitant mastopexy or fat grafting.
Linked arm/group(s): Intact Aesthetic Breast Implant Surveillance Cohort.
Baseline and annual high-resolution ultrasound will assess implant integrity.
Suspicious or indeterminate findings will undergo MRI according to the locked diagnostic algorithm.
Rupture is confirmed by MRI, operative inspection, or both.
Linked arm/group(s): Intact Aesthetic Breast Implant Surveillance Cohort.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to First Confirmed Breast Implant Rupture
Time Frame: From cohort entry through years of prospective follow-up. 10 TO 12 YEARS
|
Implant-level time from cohort entry to the first MRI- or surgically confirmed full-thickness implant shell rupture.
Implant age is used as the survival time scale with delayed entry at age on enrollment.
Contralateral implants are accounted for by patient-level clustering.
|
From cohort entry through years of prospective follow-up. 10 TO 12 YEARS
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rupture-Free Survival by Implant Age
Time Frame: 12 YEARS
|
Kaplan-Meier or model-based probability of remaining free of confirmed rupture at prespecified implant ages, using delayed-entry methods.
|
12 YEARS
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: juan velez, MD, plastic surgery
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Glener AD, Sergesketter AR, Adams WP Jr. Outcomes of In-Office, High Resolution Ultrasound Silicone Breast Implant Surveillance by Plastic Surgeons. Aesthet Surg J. 2024 Dec 12;45(1):48-55. doi: 10.1093/asj/sjae165.
- Hadad E, Klein D, Seligman Y, Wiser I, Heller L. Sub-muscular plane for augmentation mammoplasty patients increases silicone gel implant rupture rate. J Plast Reconstr Aesthet Surg. 2019 Mar;72(3):419-423. doi: 10.1016/j.bjps.2018.11.009. Epub 2018 Nov 22.
- Hadad E, Sualhi I, Legarda C, Seligman Y, Sorkin A, Dor O, Menashe S, Heller L, Wiser I. Silicone breast implant rupture is more prevalent in the dominant limb side: A retrospective cohort study. J Plast Reconstr Aesthet Surg. 2023 May;80:126-132. doi: 10.1016/j.bjps.2023.02.016. Epub 2023 Feb 20.
- Paolini G, Firmani G, Briganti F, Macino M, Nigrelli S, Sorotos M, Santanelli di Pompeo F. Assessment of Risk Factors for Rupture in Breast Reconstruction Patients with Macrotextured Breast Implants. Aesthetic Plast Surg. 2023 Apr;47(2):517-530. doi: 10.1007/s00266-022-03118-9. Epub 2022 Oct 13.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 12, 2014
Primary Completion (Actual)
January 1, 2026
Study Completion (Estimated)
December 15, 2026
Study Registration Dates
First Submitted
September 2, 2026
First Submitted That Met QC Criteria
September 2, 2026
First Posted (Actual)
September 9, 2026
Study Record Updates
Last Update Posted (Actual)
September 9, 2026
Last Update Submitted That Met QC Criteria
September 2, 2026
Last Verified
September 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 020
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
not contempled in the patient informed concent
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.